Thanks Little T. The irony is we are trading less than July 2013 when Trofinetide was at a similar stage to what NNZ-2591 will be in a few weeks time.
Back in June 2013 Neuren received Fast Track designation for Trofinetide (called NNZ-2566 at the time) and the first Phase 2 trial commenced in April. Based on the completion of Phase 1 being imminent, we will be at the same stage for NNZ-2591 shortly.
It is almost like the market is not attributing any value for the last 7.5 years of clinical development (all successful I might add). Since then Neuren has completed four (4) successful Phase 2 trials for Trofinetide. Hard to believe the market cap is the same as mid 2013 considering what has been achieved and how far ahead (Clinical Development pathway wise) Neuren is against all other clinical development bios on the ASX.
Hopefully the irrationality ends sooner than later.
NEU Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)